Physician profile
Man Cho
NPI 1902952559
$4,002.75
in general payments reported to CMS, 2019-2025
16 companies · $897 in 2025
The $897 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $310 · 2021: $690 · 2022: $722 · 2023: $272 · 2024: $195 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.09 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $832.59 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.07 | 2021-2025 | Caplyta |
| Alkermes, INC. | $422.27 | 2021-2025 | Lybalvi, Aristada |
| Allergan, INC. | $317.31 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $252.67 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $218.26 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $171.70 | 2019 | |
| Neurocrine Biosciences, INC. | $115.98 | 2023 | Ingrezza |
| Smith+Nephew, INC. | $73.29 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $63.84 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $55.85 | 2024-2025 | Rexulti |
| Lundbeck LLC | $24.89 | 2019 | |
| Almatica Pharma LLC | $24.52 | 2022 | |
| Integra Lifesciences Corporation | $18.58 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novum Pharma, LLC | $17.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Man Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.